PFE Pfizer Inc.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
Calendar
7 May 20
4 Jun 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | 12.03B | 12.68B | 13.26B | 13.12B | |
| Net income | 3.41B | 7.68B | 5.06B | 3.89B | |
| Diluted EPS | 0.61 | 1.36 | 0.89 | 0.68 | |
| Net profit margin | 28.35% | 60.60% | 38.12% | 29.65% | |
| Operating income* | 4.27B | 11.13B | 4.52B | 4.68B | |
| Net change in cash | -634M | 1B | -153M | 798M | |
| Cash on hand | 2.15B | 2.79B | 1.78B | 1.94B | |
| Cost of revenue | 2.38B | 2.6B | 2.58B | 2.43B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 53.65B | 52.55B | 52.82B | 48.85B | |
| Net income | 11.19B | 21.36B | 7.25B | 6.99B | |
| Diluted EPS | 1.87 | 3.52 | 1.17 | 1.11 | |
| Net profit margin | 20.85% | 40.64% | 13.72% | 14.30% | |
| Operating income* | 13.17B | 13.53B | 9.51B | 10.14B | |
| Net change in cash | -203M | -1.25B | -1.05B | 298M | |
| Cash on hand | 1.14B | 1.34B | 2.6B | 3.64B | |
| Cost of revenue | 11.25B | 11.23B | 12.32B | 9.65B |
Financial data from Pfizer earnings reports. *Asterisk values are approximate.
Recent insider trades
| Date | Owner | Security | Transaction | Code | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|
| 29 May 20 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Aquire A | 38.19 | 13 | 496.47 | 77,549 |
| 29 May 20 | John D Young | Phantom Stock Units SSP Common Stock | Grant | Aquire A | 38.19 | 11 | 420.09 | 46,632 |
| 29 May 20 | Dawn Rogers | Phantom Stock Units SSP Common Stock | Grant | Aquire A | 38.19 | 52 | 1.99K | 15,996 |
| 29 May 20 | Rady A Johnson | Phantom Stock Units SSP Common Stock | Grant | Aquire A | 38.19 | 4 | 152.76 | 5,521 |
| 29 May 20 | Jennifer B. Damico | Phantom Stock Units SSP Common Stock | Grant | Aquire A | 38.19 | 31 | 1.18K | 9,954 |
Institutional ownership Q1 2020
70.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2351 |
| Opened positions | 115 |
| Closed positions | 227 |
| Increased positions | 960 |
| Reduced positions | 1080 |
13F shares |
Current |
|---|---|
| Total value | 1.38T |
| Total shares | 3.9B |
| Total puts | 34.5M |
| Total calls | 24.3M |
| Total put/call ratio | 1.4 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 461.98M | $15.08B |
| BLK BlackRock | 424.07M | $13.84B |
| STT State Street | 292.62M | $9.55B |
| Capital World Investors | 224.81M | $7.34B |
| Wellington Management | 218.68M | $7.14B |
| Geode Capital Management | 89.95M | $2.93B |
| BAC Bank of America | 86.67M | $2.83B |
| NTRS Northern Trust | 70.02M | $2.29B |
| State Farm Mutual Automobile Insurance | 56.54M | $1.85B |
| BK Bank Of New York Mellon | 56.09M | $1.83B |
Financial report summary
?Competition
Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Cypress Bioscience • Celldex Therapeutics • Poniard Pharmaceuticals • Imclone Systems • Acura PharmaceuticalsRisks
- DEPENDENCE ON KEY IN-LINE PRODUCTS
- RESEARCH AND DEVELOPMENT INVESTMENT
- SPECIALTY PHARMACEUTICALS
- PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
- BIOPHARMACEUTICAL WHOLESALERS
- BUSINESS DEVELOPMENT ACTIVITIES
- PRICING AND REIMBURSEMENT
- DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
- INTERACTIONS WITH HEALTHCARE PROFESSIONALS AND GOVERNMENT OFFICIALS
- CHANGES IN LAWS AND ACCOUNTING STANDARDS
- ENVIRONMENTAL CLAIMS AND PROCEEDINGS
- THIRD PARTY INTELLECTUAL PROPERTY CLAIMS
- INFORMATION TECHNOLOGY AND SECURITY
- PENDING COMBINATION OF UPJOHN WITH MYLAN
- CONSUMER HEALTHCARE JOINT VENTURE WITH GSK
- THE GLOBAL ECONOMIC ENVIRONMENT
- FOREIGN EXCHANGE AND INTEREST RATE RISK
- MARKET FLUCTUATIONS IN OUR EQUITY INVESTMENTS
- COST AND EXPENSE CONTROL/UNUSUAL EVENTS/FAILURE TO REALIZE THE ANTICIPATED BENEFITS OF STRATEGIC INITIATIVES AND ACQUISITIONS
- INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
Abrilada, absorbing, academic, accurately, adding, Aid, air, AML, amplify, Amsparity, ankylosing, antiviral, apparently, Appellate, arisen, axial, barring, battle, BCG, benchmark, BioNTech, bladder, BRAF, Branch, Brazilian, capsule, cetuximab, Chantix, chemoradiotherapy, cleaning, combat, commensurate, compel, comply, concentrate, confirmatory, confronting, contact, CRC, Cresemba, CRL, CRT, custodian, cytarabine, Daurismo, delinquency, denial, distancing, doctor, duration, EBITDA, eliminating, enjoined, enrolled, enrollment, Erbitux, fiduciary, fighting, Florida, forma, Fosun, franchise, frequently, glasdegib, home, IBT, idiopathic, ImClone, immaterial, inappropriate, Indenture, ineffective, interbank, interventional, intraperiod, intubation, investee, Irrungattukottai, issuer, job, join, joined, juvenile, low, Lyme, MabThera, macroeconomic, margin, mCSPC, Mellon, Mexican, mild, mRNA, NDMA, novo, NYU, Ono, operationally, outbreak, oversee, pandemic, parallel, payout, peak, penetration, perpetual, peso, physical, plaque, pool, potent, precipitate, preliminarily, preplanned, prevalent, proceed, prolonged, proprietary, protease, psoriatic, PTAB, rapid, raw, rebound, recoup, recouped, recruitment, redecide, refilling, refocused, reliant, repay, respond, responded, responding, restart, restored, resume, ritlecitinib, Roche, shortly, slowdown, society, somatrogon, specialty, stabilized, statistically, stemming, stone, strict, succeeded, Sugen, suggest, suitability, Summarized, superior, suppurativa, surface, surgical, survival, tolerated, Track, tracked, tracking, trajectory, transmission, transport, travel, troubled, underserved, unemployment, unforeseen, unprecedented, unsuccessful, untreated, unturned, upward, vacated, VAI, Valneva, varenicline, viable, visit, Viwit, Vyndamax, wake, widespread, yuan, Zantac, Zavicefta, Zinforo
Removed:
accountability, accountable, achieving, achondroplasia, activating, actuarial, adjust, advocate, aforementioned, aggressive, aging, Alembic, amounted, anticipation, AOCI, applied, arm, arrive, Article, assistance, assured, attributed, AWP, Azar, BeneFIX, bidding, bioequivalence, bioequivalent, bipartisan, borrowing, bosutinib, breakthrough, Brexit, Bringing, British, call, callable, Cangialosi, capability, cease, centralization, centralized, cervix, channel, Citibank, clostridium, cohesive, collaboratively, colon, commence, Communication, considerable, Consolidation, constant, Conversely, Cooperation, costly, Council, counterclaim, criteria, decided, declaration, declaratory, declining, dedicated, deductible, delivered, demanding, demonstrated, demonstrating, dependent, diagnose, Dilution, disaggregate, discontinuation, discount, discounted, discover, dismissal, disputed, dissolving, diversity, dosing, dramatic, dramatically, dwarfism, dynamic, earlier, earliest, effectively, efficiently, EGFR, EH, electorate, emphasized, employ, encounter, encouraging, enhancing, entitlement, epidermal, ertugliflozin, Essential, establishing, exacerbated, exceed, execution, exercise, exercised, expedient, expensive, explanation, export, failing, feature, Finalizing, FL, fleet, flexibility, flexible, forestalling, formally, Fragmin, framework, fraud, gap, Gavi, generating, genetic, Genotropin, Goldman, grant, hard, headcount, hemophilia, Herceptin, hindsight, Hisun, House, identification, IH, immunization, implicit, improving, Imputed, influence, inhalation, input, intensive, internally, invalidate, issuing, judicial, junction, landscape, lease, legislative, LEP, leveraging, licensed, Lisbon, Loretta, managerial, matrix, MCC, measuring, Medrol, meeting, met, Michigan, midterm, migrate, minimum, model, modernize, modestly, modify, moving, MSN, multilateral, municipal, mutual, negatively, negotiated, NOAC, nonemployee, notification, NYSE, OAI, OECD, officially, optimal, optimization, orally, originator, outlining, package, PAP, Parliament, participate, passed, patchwork, path, Peripheral, PF, Pharmacology, Portage, pose, positioning, powder, practical, preclude, premarket, premium, President, Prism, Pristiq, privately, promising, promote, promoted, propionate, proportional, provincial, prudent, PsA, pursuit, QCE, quickly, rationalizing, realigning, reallocated, rebate, receptor, reclassification, rectum, redeploy, refacto, referencing, referendum, refuse, register, reinvested, relocate, remediate, renal, renamed, rent, rental, repatriated, replace, represented, requiring, Residual, retirement, retrospectively, reward, Rheumatology, rivipansel, robust, ROU, round, routine, Roxane, salmeterol, screen, scrutiny, secure, seize, Senate, separately, serving, SFJ, shift, Shire, shortage, sickle, signal, simplification, simplified, skip, source, space, statute, stop, streamline, stronger, sublease, suboptimal, subsequently, substituted, sufficiently, supplier, surrogate, sustainability, sustained, switch, tablet, targeting, technically, technological, tendering, thereunder, transparency, trastuzumab, Treaty, trend, true, Tygacil, ulcerative, Unallocated, unclear, unconstitutional, undiscounted, unified, Unregistered, upgrade, Urbanization, usage, variant, vast, Vfend, Vice, virtually, weaken, wild, Xyntha, Zyvox
Financial reports
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
22 Feb 18
Current reports
8-K
Entry into a Material Definitive Agreement
1 Jun 20
8-K
Other Events
28 May 20
8-K
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
22 May 20
8-K
Pfizer Prices $4,000,000,000 Debt Offering
19 May 20
8-K
Pfizer Reports First-quarter 2020 Results
28 Apr 20
8-K
Submission of Matters to a Vote of Security Holders
24 Apr 20
8-K
Susan Desmond-hellmann Elected to Pfizer’s Board of Directors
2 Apr 20
8-K
Other Events
27 Mar 20
8-K
Susan Hockfield Elected to Pfizer’s Board of Directors
4 Mar 20
8-K
Departure of Directors or Certain Officers
2 Mar 20
Registration and prospectus
425
Business combination disclosure
1 Jun 20
424B5
Prospectus supplement for primary offering
20 May 20
FWP
Free writing prospectus
19 May 20
424B3
Prospectus supplement
18 May 20
425
Business combination disclosure
30 Apr 20
424B5
Prospectus supplement for primary offering
26 Mar 20
425
Business combination disclosure
26 Mar 20
FWP
Free writing prospectus
25 Mar 20
424B3
Prospectus supplement
25 Mar 20
25-NSE
Exchange delisting
6 Mar 20
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 20
PX14A6G
Letter to shareholders
6 Apr 20
PX14A6G
Letter to shareholders
3 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Mar 20
DEF 14A
Definitive proxy
13 Mar 20
PX14A6G
Letter to shareholders
8 Apr 19
DEFA14A
Additional proxy soliciting materials
2 Apr 19
PX14A6G
Letter to shareholders
21 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
14 Mar 19
Other
CT ORDER
Confidential treatment order
15 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
7 Mar 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
31 Jan 17
NO ACT
No action letter
26 Jan 17
NO ACT
No action letter
10 Jan 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
4
PFIZER / JOHN D YOUNG ownership change
1 Jun 20
4
PFIZER / DAWN ROGERS ownership change
1 Jun 20
4
PFIZER / RADY A JOHNSON ownership change
1 Jun 20
4
PFIZER / JENNIFER B. DAMICO ownership change
1 Jun 20
4
PFIZER / ALBERT BOURLA ownership change
1 Jun 20
4
PFIZER / JOHN D YOUNG ownership change
19 May 20
4
PFIZER / DAWN ROGERS ownership change
19 May 20
4
PFIZER / RADY A JOHNSON ownership change
19 May 20
4
PFIZER / JENNIFER B. DAMICO ownership change
19 May 20
4
PFIZER / ALBERT BOURLA ownership change
19 May 20
Patents
GRANT
Utility
Immunogenic glycoprotein conjugates
2 Jun 20
Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
GRANT
Utility
GLP-1 receptor agonists and uses thereof
2 Jun 20
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
GRANT
Utility
Imidazopyridazine compounds
2 Jun 20
Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young, Patrick Robert Verhoest
APP
Utility
Neisseria Meningitidis Compositions and Methods Thereof
28 May 20
In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide.
APP
Utility
Compositions and Methods Relating to a Mutant Clostridium Difficile Toxin
28 May 20
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.